drugset
drugset / Trial / NCT03583125

Study of EOC317 in Chinese Patients With Advanced Solid Tumors

NCT03583125 ↗

Phase 1 Unknown 140 enrolled Taizhou EOC Pharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.

Timeline

Start
2018-05-29
Primary completion
2020-02-29
Completion
2020-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject EOC317 Unknown 5 mg Oral
Subject EOC317 Unknown 10 mg Oral
Subject EOC317 Unknown 20 mg Oral
Subject EOC317 Unknown 30 mg Oral
Subject EOC317 Unknown 45 mg Oral
Subject EOC317 Unknown 60 mg Oral

Indications

cancer